FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells
SRC transformed SW620 cells were a kind gift from Serge Roche (CNRS and University of Montpellier). TRIB2 plasmids were a kind gift from Patrick Eyers (University of Liverpool) and the protein was produced and purified by Andras Lang. This work was funded by grants from the Generalitat de Catalunya...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:20.500.12328/4488 |
| Acceso en línea: | http://hdl.handle.net/20.500.12328/4488 https://dx.doi.org/10.1016/j.biopha.2024.117325 |
| Access Level: | acceso abierto |
| Palabra clave: | Reutilització de fàrmacs Antivirals d'acció directa Orientació Src en tumors sòlids Akt Proteïna receptora de cèl·lules epitelials tirosina Quinasa Receptor d'efrina tipus A 2 ECK Receptor EPH A2 Proteïna quinasa B Reutilización de fármacos Antivirales de acción directa Orientación a Src en tumores sólidos Receptor de células epiteliales de la proteína tirosina quinasa Receptor efrina tipo A 2 Proteína quinasa B Drug repurposing Direct-acting antivirals Src targeting in solid tumors Epithelial Cell Receptor Protein Tyrosine Kinase Ephrin type-A receptor 2 EPH receptor A2 Protein kinase B 61 616 |
| Sumario: | SRC transformed SW620 cells were a kind gift from Serge Roche (CNRS and University of Montpellier). TRIB2 plasmids were a kind gift from Patrick Eyers (University of Liverpool) and the protein was produced and purified by Andras Lang. This work was funded by grants from the Generalitat de Catalunya (2021 SGR 425) and the Spanish “Agencia Estatal de Investigacion´ ”: PDC2021–121629-I00 (with the support of the Recovery and Resilience Mechanism and NextGenerationEU funding); PID2019–104914RB-I00, and PID2022–139160OB-I00 (with a contribution from European Regional Development funds). |
|---|